- Home
- MNPR vs DSM Comparison
MNPR vs DSM Comparison
Compare MNPR & DSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNPR | DSM |
|---|---|---|
| Founded | 2014 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.9M | 306.0M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | MNPR | DSM |
|---|---|---|
| Price | $62.74 | $6.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $107.00 | N/A |
| AVG Volume (30 Days) | ★ 164.9K | 80.3K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.97% |
| EPS Growth | ★ 54.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.40 | $5.45 |
| 52 Week High | $105.00 | $6.30 |
Technical Indicators
Market Signals| Indicator | MNPR | DSM |
|---|---|---|
| Relative Strength Index (RSI) | 56.98 | 42.76 |
| Support Level | $51.71 | $5.94 |
| Resistance Level | $67.90 | $6.22 |
| Average True Range (ATR) | 5.65 | 0.07 |
| MACD | 0.27 | -0.02 |
| Stochastic Oscillator | 68.24 | 28.33 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.